compounded semaglutide injection for Weight Loss — Injectable FDA Warns on Certain Forms

Electrolytes like sodium and potassium should also be checked, since rapid weight loss sometimes shifts fluid balance

For patients managing diabetes with insulin or sulfonylureas alongside GLP-1 therapy, hypoglycemia becomes a concern

Phase 2 data showed weight loss exceeding 24 percent at 48 weeks, potentially making it the most powerful weight loss medication ever developed

What matters is the overall trend

Others may pause treatment, experience weight regain, and choose to restart under medical supervision

The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease, a condition projected to affect nearly 2 billion worldwide by 2050